1
|
Shintaku S, Kawanishi H, Banshodani M, Moriishi M, Takahashi N, Tsuchiya S. Efficacy of drug-coated balloon catheters for patients with short-term recurrent dysfunction of arteriovenous fistula. J Vasc Access 2024:11297298241245853. [PMID: 38641588 DOI: 10.1177/11297298241245853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/21/2024] Open
Abstract
BACKGROUND In this study, we aimed at clarifying the usefulness of drug-coated balloon catheters (DCBs) for arteriovenous fistulas (AVFs) that repeatedly undergo restenosis over a short period and to examine the factors that influence the patency period after DCB use. METHODS This retrospective observational study was conducted using IN.PACT AV in 29 cases of AVFs with repeated restenosis within approximately 3 months, and temporary patency before and after DCB use in the same patients was compared. For target participants, the flow volume, resistive index (RI), and vascular diameter of the brachial artery were measured using an ultrasound diagnostic device. Stenosis diameter, reference vessel diameter, and stenosis length of the lesion were measured before and after DCB dilatation using digital subtraction angiography. RESULTS Before DCB angioplasty, the postintervention primary patency at 3 months was 66%, and the average interval was 92 ± 21 days (mean ± standard deviation). After DCB angioplasty, the postintervention primary patency rates at 3 and 6 months were 92% and 36%, respectively. The postintervention primary patency was significantly higher after than before DCB angioplasty (p < 0.0001). A sub-analysis was performed on 25 patients who were followed up for 4 months or more after DCB. The RI values before and after dilatation with DCB significantly differed between the patency group 4 or more months after DCB and the patency group less than 4 months after DCB. CONCLUSION For AVFs that require frequent PTA over a short period of time, DCB improved the patency rate 3 months after PTA, but the improvement effect at 6 months was limited. The effect of DCB on prolonging the patency rate of AVFs that require frequent PTA over a short period of time may be correlated with the RI value before and after PTA.
Collapse
Affiliation(s)
- Sadanori Shintaku
- Department of Kidney Disease and Blood Purification Therapy, Tsuchiya General Hospital, Hiroshima, Japan
| | - Hideki Kawanishi
- Department of Kidney Disease and Blood Purification Therapy, Tsuchiya General Hospital, Hiroshima, Japan
| | - Masataka Banshodani
- Department of Kidney Disease and Blood Purification Therapy, Tsuchiya General Hospital, Hiroshima, Japan
| | | | | | - Shinichiro Tsuchiya
- Department of Kidney Disease and Blood Purification Therapy, Tsuchiya General Hospital, Hiroshima, Japan
| |
Collapse
|
2
|
Banshodani M, Kawanishi H, Moriishi M, Takahashi N, Shintaku S, Tsuchiya S. Hospitalizations for non-SARS-CoV-2 respiratory infectious diseases among patients on hemodialysis: A comparison before and during the coronavirus disease 2019 pandemic. Ther Apher Dial 2024; 28:240-245. [PMID: 37905782 DOI: 10.1111/1744-9987.14078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Revised: 09/28/2023] [Accepted: 10/11/2023] [Indexed: 11/02/2023]
Abstract
INTRODUCTION The impact of coronavirus disease 2019 (COVID-19) infection control on other infections in patients with dialysis has not received sufficient consideration. METHODS We compared hospitalization and mortality rates among patients who underwent hemodialysis (HD) at three dialysis centers before (March 2018-February 2020) and during (March 2020-February 2022) the COVID-19 pandemic. RESULTS This study included 1696 patients undergoing HD (mean age, 70 years; 1099 men). Compared to before the COVID-19 pandemic, the emergency hospitalization rate (per 100 dialysis patient-years) for non-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) respiratory infectious diseases (IDs) (7.0 vs. 4.1, p < 0.001) significantly decreased during the COVID-19 pandemic, whereas the hospitalization rates for other IDs were comparable. The mortality rates for non-SARS-CoV-2 respiratory IDs were comparable before and during the COVID-19 pandemic. CONCLUSIONS Hospitalizations for non-SARS-CoV-2 respiratory IDs among patients undergoing HD may have decreased owing to the implementation of infection control measures for COVID-19.
Collapse
Affiliation(s)
- Masataka Banshodani
- Department of Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Hideki Kawanishi
- Department of Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Misaki Moriishi
- Department of Internal Medicine, Akane-Foundation, Nakajima Tsuchiya Clinic, Hiroshima, Japan
| | - Naoko Takahashi
- Department of Internal Medicine, Akane-Foundation, Omachi Tsuchiya Clinic, Hiroshima, Japan
| | - Sadanori Shintaku
- Department of Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Shinichiro Tsuchiya
- Department of Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| |
Collapse
|
3
|
Kawai Y, Maeda K, Moriishi M, Kawanishi H, Masaki T. Comparison of the pre-dilution and post-dilution methods for online hemodiafiltration. J Artif Organs 2024; 27:48-56. [PMID: 37010653 DOI: 10.1007/s10047-023-01391-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2022] [Accepted: 03/12/2023] [Indexed: 04/04/2023]
Abstract
Online hemodiafiltration (OL-HDF) is a treatment modality using diffusion and ultrafiltration. There are two types of dilution methods in OL-HDF: pre-dilution, which is commonly provided in Japan, and post-dilution, which is commonly provided in Europe. The optimal OL-HDF method for individual patients is not well studied. In this study, we compared the clinical symptoms, laboratory data, spent dialysate, and adverse events of pre- and post-dilution OL-HDF. We conducted a prospective study of 20 patients who underwent OL-HDF between January 1, 2019 and October 30, 2019. Their clinical symptoms and dialysis efficacy were evaluated. All patients underwent OL-HDF every 3 months in the following sequence: first pre-dilution, post-dilution, and second pre-dilution. We evaluated 18 patients for the clinical study and 6 for the spent dialysate study. No significant differences in spent dialysates regarding small and large solutes, blood pressure, recovery time, and clinical symptoms were observed between the pre- and post-dilution methods. However, the serum α1-microglobulin level in post-dilution OL-HDF was lower than that in pre-dilution OL-HDF (first pre-dilution: 124.8 ± 14.3 mg/L; post-dilution: 116.6 ± 13.9 mg/L; second pre-dilution: 125.8 ± 13.0 mg/L; first pre-dilution vs. post-dilution, post-dilution vs. second pre-dilution, and first pre-dilution vs. second pre-dilution: p = 0.001, p < 0.001, and p = 1.000, respectively). The most common adverse event was an increase in transmembrane pressure in the post-dilution period. Compared to pre-dilution, the post-dilution method decreased the α1-microglobulin level; however, there were no significant differences in clinical symptoms or laboratory data.
Collapse
Affiliation(s)
- Yusuke Kawai
- Department of Renal Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, 3-30 Nakajimacho, Naka-Ku, Hiroshima, 730-8655, Japan
| | - Kazuya Maeda
- Department of Nephrology, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan.
| | - Misaki Moriishi
- Department of Renal Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, 3-30 Nakajimacho, Naka-Ku, Hiroshima, 730-8655, Japan
| | - Hideki Kawanishi
- Department of Renal Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, 3-30 Nakajimacho, Naka-Ku, Hiroshima, 730-8655, Japan
| | - Takao Masaki
- Department of Nephrology, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan.
| |
Collapse
|
4
|
Harada W, Banshodani M, Shimamoto F, Shintaku S, Moriishi M, Masaki T, Kawanishi H. Encapsulating Peritoneal Sclerosis 43 Years after Distal Gastrectomy for Early Gastric Cancer. Intern Med 2024; 63:659-663. [PMID: 37468244 PMCID: PMC10982008 DOI: 10.2169/internalmedicine.2037-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Accepted: 06/11/2023] [Indexed: 07/21/2023] Open
Abstract
We herein report a case of encapsulating peritoneal sclerosis (EPS) in a patient without chronic kidney disease after gastrectomy. A 69-year-old man underwent distal gastrectomy for early gastric cancer at 25 years old. After 43 years, he developed bowel obstruction and underwent enterolysis of the encapsulated small intestine. A pathological examination of the capsular membranes revealed inflammation, foam, and giant cells that destroyed foreign substances. The patient was discharged 1.5 months later. Foreign body reactions to surgical instruments used in gastrectomy are considered a cause of EPS. EPS due to foreign body reactions to surgical instruments should also be considered in such cases.
Collapse
Affiliation(s)
- Wataru Harada
- Department of Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Japan
- Department of Nephrology, Hiroshima University Hospital, Japan
| | - Masataka Banshodani
- Department of Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Japan
| | - Fumio Shimamoto
- Diagnostic Pathology, Pathology Clinic, Japan
- Department of Nursing, Faculty of Health Sciences Dean, Hiroshima Cosmopolitan University, Japan
| | - Sadanori Shintaku
- Department of Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Japan
| | - Misaki Moriishi
- Department of Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Japan
| | - Takao Masaki
- Department of Nephrology, Hiroshima University Hospital, Japan
| | - Hideki Kawanishi
- Department of Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Japan
| |
Collapse
|
5
|
Hashimoto S, Banshodani M, Marubayashi S, Shintaku S, Moriishi M, Tsuchiya S, Kawanishi H. Iatrogenic arteriovenous fistula in the brachial artery after percutaneous coronary intervention in a patient with end stage kidney disease. J Vasc Access 2023:11297298231158427. [PMID: 36856231 PMCID: PMC9982409 DOI: 10.1177/11297298231158427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Accepted: 02/02/2023] [Indexed: 03/02/2023] Open
Abstract
Iatrogenic arteriovenous fistula (AVF) is a complication accompanying venous and arterial puncture. Herein we report a case of ligation closure of an iatrogenic AVF in the brachial artery after percutaneous coronary intervention (PCI) for the patient with end-stage kidney disease (ESKD). A 68-year-old woman presented with a history of several coronary angiographies (CAG) and PCI through the right brachial artery. After PCI, the patient experienced a thrill in the right elbow. Two years later, the patient initiated hemodialysis (HD) using a temporary HD catheter for ESKD and congestive cardiac failure. Ultrasonography and computed tomographic angiography revealed an iatrogenic AVF between the right brachial artery and the medial brachial vein. Blood flow in the brachial artery was 760 mL/min. However, the iatrogenic AVF was unusable as vascular access for HD, and prior ligation closure of the iatrogenic AVF was performed, considering the risk of cardiac failure due to double AVFs after the creation of a new AVF for HD. Subsequently, a new radial-cephalic AVF was created in the left forearm. Therefore, clinicians should consider the possibility of iatrogenic AVF in patients with ESKD having a history of CAG or PCI.
Collapse
Affiliation(s)
- Shinji Hashimoto
- Department of Kidney Disease and Blood
Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Naka-ku,
Hiroshima, Japan
| | - Masataka Banshodani
- Department of Kidney Disease and Blood
Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Naka-ku,
Hiroshima, Japan
| | - Seiji Marubayashi
- Department of Kidney Disease and
Dialysis Therapy, Akane-Foundation, Ajina Tsuchiya Hospital, Ajina, Hatsukaichi-shi,
Hiroshima, Japan
| | - Sadanori Shintaku
- Department of Kidney Disease and Blood
Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Naka-ku,
Hiroshima, Japan
| | - Misaki Moriishi
- Department of Kidney Disease and Blood
Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Naka-ku,
Hiroshima, Japan
| | - Shinichiro Tsuchiya
- Department of Kidney Disease and Blood
Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Naka-ku,
Hiroshima, Japan
| | - Hideki Kawanishi
- Department of Kidney Disease and Blood
Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Naka-ku,
Hiroshima, Japan
| |
Collapse
|
6
|
Banshodani M, Kawanishi H, Hirai T, Kawai Y, Hashimoto S, Shintaku S, Moriishi M, Marubayashi S, Tsuchiya S. The predictive markers of severity and mortality in hospitalized hemodialysis patients with COVID-19 during Omicron epidemic. Ther Apher Dial 2023. [PMID: 36691364 DOI: 10.1111/1744-9987.13970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Revised: 12/05/2022] [Accepted: 01/20/2023] [Indexed: 01/25/2023]
Abstract
INTRODUCTION Predictive markers and prognosis remain unclear in hospitalized hemodialysis (HD) patients with coronavirus disease 2019 (COVID-19) during the Omicron epidemic. METHODS We evaluated characteristics, laboratory parameters, and outcomes in hospitalized HD patients with COVID-19 (n = 102) at two centers between January and April 2022. RESULTS The 30-day mortality rate was higher in moderate-critical group (n = 43) than mild group (n = 59) (16.3% vs. 1.7%; p = 0.007), and higher in patients with lower CC chemokine ligand 17 (CCL17) levels (<95.0 pg/mL) compared with normal CCL17 levels (19.0% versus 4.9%; p = 0.03). In multivariate analyses, a low CCL17 level (p = 0.003) was associated with moderate-critical conditions, and moderate-critical conditions (p = 0.04) were associated with 30-day mortality, whereas CCL17 was not associated with 30-day mortality. CONCLUSIONS COVID-19 remains a fatal complication, and CCL17 was a predictive marker of severity in hospitalized HD patients during the Omicron epidemic.
Collapse
Affiliation(s)
- Masataka Banshodani
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Hideki Kawanishi
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Takayuki Hirai
- Kidney Disease and Dialysis, Akane-Foundation, Ajina Tsuchiya Hospital, Hatsukaichi, Japan
| | - Yusuke Kawai
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Shinji Hashimoto
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Sadanori Shintaku
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Misaki Moriishi
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Seiji Marubayashi
- Kidney Disease and Dialysis, Akane-Foundation, Ajina Tsuchiya Hospital, Hatsukaichi, Japan
| | - Shinichiro Tsuchiya
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| |
Collapse
|
7
|
Banshodani M, Marubayashi S, Kawai Y, Hashimoto S, Shintaku S, Moriishi M, Tsuchiya S, Kawanishi H. The Impact of Tunneled Central Venous Hemodialysis Catheter on Mortality of Elderly Hemodialysis Patients Hospitalized in a Long-Term Care Hospital. Blood Purif 2023; 52:392-400. [PMID: 36634633 DOI: 10.1159/000528575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Accepted: 12/04/2022] [Indexed: 01/14/2023]
Abstract
INTRODUCTION The association between tunneled central venous hemodialysis catheters (TCVCs) and mortality in hospitalized elderly hemodialysis (HD) patients remains unclear. METHODS This retrospective observational study was conducted in a long-term care hospital. We evaluated the association between TCVC and mortality in HD patients hospitalized between 2015 and 2020. RESULTS A total of 463 patients were compared: TCVC group (n = 53) and non-TCVC group (n = 410) including arteriovenous fistula (AVF, n = 369), arteriovenous graft (AVG, n = 30), and superficialized brachial artery (SBA, n = 11). The mean ages were 80 and 78 years in the TCVC and non-TCVC groups, respectively. Overall mortality rates for all-cause and cardiovascular diseases (CVDs) were higher in the TCVC group than in the non-TCVC group (log-rank, p = 0.01, and p = 0.009). Overall mortality was higher in the TCVC group than in the AVF group (p = 0.04), but there were no significant differences between the TCVC, AVG, and SBA groups. In Cox proportional hazards regression models, age, dialysis vintage, male sex, Charlson Comorbidity Index (CCI), and serum albumin level were associated with all-cause, CVD, and infectious disease (ID) mortalities, but TCVC was not associated with all-cause (hazard ratio, 1.31; 95% confidence interval, 0.95-1.80; p = 0.1), CVD (1.54; 0.99-2.39; p = 0.051), and ID (0.91; 0.48-1.70; p = 0.8) mortalities. Among patients aged ≥80 years, with dialysis vintage ≥7 years and CCI ≥10, the overall mortality rates were comparable between the two groups. CONCLUSIONS Among elderly HD patients in the long-term care hospital, TCVC was not associated with mortality.
Collapse
Affiliation(s)
- Masataka Banshodani
- Kidney Disease and Blood Purification Therapy, Akane Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Seiji Marubayashi
- Kidney Disease and Dialysis, Akane Foundation, Ajina Tsuchiya Hospital, Hatsukaichi, Japan
| | - Yusuke Kawai
- Kidney Disease and Blood Purification Therapy, Akane Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Shinji Hashimoto
- Kidney Disease and Blood Purification Therapy, Akane Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Sadanori Shintaku
- Kidney Disease and Blood Purification Therapy, Akane Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Misaki Moriishi
- Kidney Disease and Blood Purification Therapy, Akane Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Shinichiro Tsuchiya
- Kidney Disease and Blood Purification Therapy, Akane Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Hideki Kawanishi
- Kidney Disease and Blood Purification Therapy, Akane Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| |
Collapse
|
8
|
Yamaoka M, Banshodani M, Muraoka S, Tanaka K, Kimura A, Tani H, Hashimoto S, Shiraki N, Shintaku S, Moriishi M, Tsuchiya S, Masaki T, Kawanishi H. COVID-19-associated pulmonary aspergillosis in hemodialysis patients. Clin Kidney J 2022; 15:985-991. [PMID: 35498890 PMCID: PMC8807313 DOI: 10.1093/ckj/sfac027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Indexed: 11/19/2022] Open
Abstract
Background Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a fatal complication in the general population. However, there are few reports on CAPA in patients undergoing hemodialysis (HD). Methods This retrospective observational cohort study was conducted at a single center between December 2020 and June 2021. We enrolled 21 HD patients with COVID-19 undergoing treatment and divided them into two groups, CAPA and non-CAPA (COVID-19 with and without pulmonary aspergillosis), and evaluated their characteristics, clinical outcomes and comorbidities. Results The log-rank test revealed that the 90-day survival rate after the initiation of treatment for COVID-19 was significantly lower in the CAPA (n = 6) than in the non-CAPA group (n = 15) (P = 0.0002), and the 90-day mortality rates were 66.6% and 0% in the CAPA and non-CAPA groups, respectively. In the CAPA group, four patients died due to respiratory failure (on Days 6 and 20), gastrointestinal bleeding (Day 8) and sepsis (Day 33); the reverse transcription-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remained positive when they died. The remaining two patients survived and the negative conversion of RT-PCR for SARS-CoV-2 was confirmed on Days 10 and 15. The negative conversion of serum (1, 3)-β-d-glucan (BDG) was confirmed on Day 15 in one patient; the BDG remained positive on Day 64 in the other. Conclusions CAPA is a fatal complication in HD patients and the general population. Therefore, clinicians should consider the possibility of testing for CAPA in patients undergoing HD. Mycological workups may be helpful for the early detection of CAPA.
Collapse
Affiliation(s)
- Mai Yamaoka
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
- Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan
| | - Masataka Banshodani
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Shiro Muraoka
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Kenta Tanaka
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Ayaka Kimura
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Hiroki Tani
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Shinji Hashimoto
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Nobuaki Shiraki
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Sadanori Shintaku
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Misaki Moriishi
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Shinichiro Tsuchiya
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Takao Masaki
- Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan
| | - Hideki Kawanishi
- Kidney Disease and Blood Purification Therapy, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| |
Collapse
|
9
|
Kawai Y, Banshodani M, Moriishi M, Shizukawa H, Sato T, Shintaku S, Masaki T, Kawanishi H. Penile calciphylaxis in patients with end-stage kidney disease undergoing dialysis: invasive treatment and pain management. Ther Apher Dial 2022; 26:950-959. [PMID: 34984854 DOI: 10.1111/1744-9987.13789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Revised: 11/26/2021] [Accepted: 12/29/2021] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Penile calciphylaxis is rarely reported in dialysis patients. METHODS We experienced cases of dialysis patients who had penile calciphylaxis between 2003 and 2020. RESULTS Seven patients undergoing dialysis were treated for penile necrosis (hemodialysis [HD], 5; peritoneal dialysis [PD], 1; hybrid therapy comprising PD and HD, 1). Their mean age was 62.8 years and their mean dialysis vintage 116.1 months. All had severe penile pain and were clinically diagnosed with calciphylaxis. Four received partial penectomy and three received percutaneous transluminal angioplasty (PTA) due to rapid aggravation. The number of analgesia types and the critical-care pain observation tool score significantly decreased after invasive treatment (both, P = 0.008). The 90-day and 1-year survival rates after onset were 85.7% and 57.1%, respectively. CONCLUSION In dialysis patients, penile calciphylaxis has poor prognosis; however, invasive treatments for pain management are effective. PTA may be beneficial in dialysis patients in poor condition. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Yusuke Kawai
- Artificial Organs, Akane Foundation, Tsuchiya General Hospital 3-30, Nakajimacho, Naka-ku, Hiroshima, Japan
| | - Masataka Banshodani
- Artificial Organs, Akane Foundation, Tsuchiya General Hospital 3-30, Nakajimacho, Naka-ku, Hiroshima, Japan
| | - Misaki Moriishi
- Artificial Organs, Akane Foundation, Tsuchiya General Hospital 3-30, Nakajimacho, Naka-ku, Hiroshima, Japan
| | - Hiroko Shizukawa
- Dermatology, Akane Foundation, Tsuchiya General Hospital 3-30, Nakajimacho, Naka-ku, Hiroshima, Japan
| | - Tomoyasu Sato
- Radiology, Akane Foundation, Tsuchiya General Hospital 3-30, Nakajimacho, Naka-ku, Hiroshima, Japan
| | - Sadanori Shintaku
- Artificial Organs, Akane Foundation, Tsuchiya General Hospital 3-30, Nakajimacho, Naka-ku, Hiroshima, Japan
| | - Takao Masaki
- Department of Nephrology, Hiroshima University Hospital 1-2-3, Kasumi, Minami-ku, Hiroshima, Japan
| | - Hideki Kawanishi
- Artificial Organs, Akane Foundation, Tsuchiya General Hospital 3-30, Nakajimacho, Naka-ku, Hiroshima, Japan
| |
Collapse
|
10
|
Takahashi N, Yoshizawa T, Kumagai J, Kawanishi H, Tsuchiya S, Moriishi M, Masaki T. Effectiveness of a treatment algorithm for hemodialysis-associated pruritus in terms of changes in medications. Ren Replace Ther 2021. [DOI: 10.1186/s41100-021-00339-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Abstract
Background
Hemodialysis-associated pruritus (HAP) is a serious complication that occurs in 60–80% of hemodialysis patients, which not only decreases quality of life but also worsens prognosis. We have developed a treatment algorithm to take a comprehensive cause-specific approach to HAP and used it at our facility since June 2009. In this treatment algorithm, moisturizers and topical steroids are used depending on skin condition and severity of pruritus; administration of nalfurafine hydrochloride is considered in treatment-resistant cases. If pruritus improves, we attempt to taper topical steroids by switching to lower potency or by dose reduction or discontinuation. Here, we examined the effectiveness of the treatment algorithm over 9 years in terms of changes in medications.
Methods
Subjects were hemodialysis patients who received treatment for HAP at our facility: 89 in May 2009 before introduction of the algorithm, and 131 in April 2013, 164 in October 2014, 190 in October 2015, 181 in October 2016, 215 in October 2017, and 224 patients in October 2018 after its introduction. A questionnaire survey was conducted on the presence of pruritus, severity (using a visual analogue scale [VAS] and Shiratori severity scores), frequency, and insomnia due to pruritus. Changes in medications were investigated using medical records and compared.
Results
The proportion of patients with pruritus decreased significantly from 96.6% in 2009 to 66.8% in 2018 (p < 0.001). Median VAS score significantly decreased from 53.0 mm in 2009 to 24.5 mm in 2018 (p < 0.001), and the proportion of patients with insomnia due to pruritus also significantly decreased from 25.8% in 2009 to 2.2% in 2018 (p < 0.001). The proportion of patients who used moisturizers significantly increased from 34.8 to 89.7% (p < 0.001). The proportion of patients receiving topical steroids decreased from 47.2 to 35.7%, but the difference was not significant (p = 0.085).
Conclusions
The treatment algorithm was shown to be useful for improving HAP, but future challenges were identified, including promoting use of lower potency topical steroids or discontinuation. Further prospective studies are required to confirm the role of each treatment intervention in a comprehensive cause-specific approach to HAP.
Collapse
|
11
|
Banshodani M, Marubayashi S, Shintaku S, Sato T, Moriishi M, Tsuchiya S, Ohdan H, Kawanishi H. Percutaneous transluminal angioplasty with carbon dioxide for peripheral arterial disease after kidney transplantation: a case report with literature review. Ren Replace Ther 2020. [DOI: 10.1186/s41100-020-00275-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
Arteriosclerosis may progress and lead to peripheral arterial disease (PAD) during the waiting period until kidney transplantation in end-stage kidney disease (ESKD) patients. Additionally, contrast-induced nephropathy (CIN) of a kidney allograft after the examination and treatment for PAD is problematic. Here, we report the case of a kidney transplant recipient with PAD in the lower extremities who underwent percutaneous transluminal angioplasty (PTA) with carbon dioxide to prevent CIN incidence.
Case presentation
A 57-year-old woman underwent a cadaveric kidney transplant when she was 49 years old. Immunosuppression was maintained with tacrolimus, methylprednisolone, and mycophenolate mofetil. Her post-transplant course was uneventful, and serum creatinine level was maintained at 1.1–1.3 mg/dL. Intermittent claudication of the lower legs began 3 years after transplantation. Under saline intravenous rehydration, computed tomographic angiographies were performed, and the patient was diagnosed with PAD in the bilateral lower extremities. Total PTA was performed thrice for PAD in the lower extremities via a combination of carbon dioxide and iodinated contrast medium to prevent CIN incidence at 3, 4, and 7 years after kidney transplantation. The patient’s recoveries were uneventful. One year later, the serum creatinine level was maintained at 0.9–1.1 mg/dL, and since then, the patient has shown no evidence of recurrence.
Conclusions
In a kidney transplant recipient with PAD, PTA with carbon dioxide was effective to minimize the volumes of iodinated contrast medium and prevent CIN incidence.
Collapse
|
12
|
Abstract
Encapsulating peritoneal sclerosis (EPS) is an intestinal obstruction syndrome in which peritoneal deterioration and intraperitoneal inflammation result in intestinal adhesions, which are covered with a fibrin capsule and cause bowel obstruction. The widespread use of peritoneal dialysis (PD) has been associated with an increase in the number of patients with this life-threatening complication. For this reason, some negative comments have been made about PD therapy. However, recent clinical studies have elucidated the pathogenesis of EPS and proposed therapeutic strategies. Currently, these facts are known: • EPS occurs in 2.5% of all patients (3.18/1000 patient-years). • A longer duration of PD is associated with a higher incidence of EPS and a poorer prognosis, indicating the involvement of peritoneal deterioration in the development of EPS. • Development of EPS involves some kind of infection. • Development of EPS frequently occurs after PD withdrawal and catheter removal. • Peritoneal lavage after PD withdrawal delays, but cannot prevent the development of EPS. • Timely administration of steroids is effective. • Surgical adhesiolysis is the optimal treatment to relieve bowel obstructions, but does not exclude the potential for re-adhesions, requiring various ingenious gastrointestinal surgical techniques.
Collapse
|
13
|
Banshodani M, Kawanishi H, Moriishi M, Shintaku S, Tsuchiya S. Association between Dialysis Modality and Infectious Diseases: Peritoneal Dialysis versus Hemodialysis. Blood Purif 2020; 50:370-379. [PMID: 33120394 DOI: 10.1159/000511041] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Accepted: 08/16/2020] [Indexed: 11/19/2022]
Abstract
INTRODUCTION For dialysis patients with end-stage kidney disease, infectious diseases (IDs) are the most common causes of hospitalization and death. However, the association between dialysis modality and IDs remains unclear. We aimed to determine the association between the dialysis modality and IDs. METHODS This retrospective observational cohort study compared the emergency hospitalization and mortality for IDs between peritoneal dialysis (PD) and hemodialysis (HD) patients. After propensity score matching, the risk factors were evaluated by the Cox proportional hazard regression models. RESULTS A total of 260 patients were compared - 130 of 135 PD and 130 of 706 HD patients. When the modality-specific ID (PD-catheter ID/peritonitis- and vascular access-related ID) was excluded, no significant differences in emergency hospitalization and mortality rates for overall IDs were observed between the PD and HD groups. Serum ferritin (HR, 2.17; CI, 1.06-4.43; p = 0.03) and Charlson Comorbidity Index (CCI) (HR, 1.24; CI, 1.01-1.52; p = 0.04) were significant predictors of emergency hospitalization for IDs, whereas age (HR, 1.12; CI, 1.05-1.19; p < 0.001), male (HR, 3.38; CI, 1.01-11.3; p = 0.048), serum alkaline phosphatase (ALP) (HR, 6.87; CI, 2.18-21.7; p = 0.001), C-reactive protein (CRP) (HR, 10.7; CI, 3.55-32.1; p < 0.001), and CCI (HR, 1.79; CI, 1.27-2.52; p < 0.001) were significant predictors of ID mortality. When modality-specific ID was included, the emergency hospitalization rate for overall IDs was higher in the PD groups, and PD was a significant predictor of emergency hospitalization for IDs, whereas no significant difference in mortality rate for overall IDs was found between the PD and HD groups. CONCLUSIONS ID events were not associated with dialysis modality when modality-specific ID was excluded, whereas the risk of modality-specific IDs was higher in PD than HD. Serum ferritin and ALP as well as age, male sex, CRP, and CCI were the risk factors for ID events.
Collapse
Affiliation(s)
- Masataka Banshodani
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan,
| | - Hideki Kawanishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Misaki Moriishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Sadanori Shintaku
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Shinichiro Tsuchiya
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| |
Collapse
|
14
|
Abstract
⋄ Background The peritoneum is impaired by exposure to biocompatible dialysis solutions. Because icodextrin peritoneal dialysis fluid (PDF) is made from cornstarch, a possibility that it induces intraperitoneal inflammation has been reported. In the present study, patients on glucose PDF were switched to icodextrin PDF and then switched back to glucose PDF. Icodextrin PDF-induced intraperitoneal inflammation was investigated based on changes in peritoneal permeability and inflammatory reactions. ⋄ Patients and Methods The subjects were 7 stable peritoneal dialysis patients (4 men, 3 women), with a mean age of 59.1 ± 3.8 years (range: 55.2 - 64.6 years). The mean duration of peritoneal dialysis was 58.3 ± 27.4 months (range: 34.3 - 97.7 months), and the cause of end-stage renal disease was chronic glomerulonephritis in all patients. For the overnight dwell, glucose PDF was changed to icodextrin PDF, and the patients returned to glucose PDF 30 months later. To evaluate peritoneal permeability, a peritoneal equilibrium test (PET) was performed, and dialysate-to-plasma (D/P) ratios of creatinine (Cr), β2-microglobulin (β2M), albumin, immunoglobulin G (IgG), and α2-macroglobulin (α2M) were measured in the overnight dialysate and serum. As markers of inflammation and fibrinolysis or coagulation, interleukin-6 (IL-6) and fibrinogen degradation products (FDPs) were measured in overnight effluent. The evaluations were made every 6 months for 36 months. ⋄ Results A significant elevation in FDP levels was detected in overnight effluent 6 months after the switch to icodextrin PDF, and IL-6 levels tended to increase. The D/P ratios of Cr, β2M, and albumin were also significantly increased, and the D/P ratios of IgG and α2M tended to increase. The D/P ratio of Cr as measured by PET was slightly increased, but the elevation was not significant. In 5 patients, after icodextrin PDF was switched back to glucose PDF at 30 months, the D/P ratios of Cr, β2M, albumin, IgG, and α2M in overnight effluent were significantly reduced. The FDP levels decreased slightly in those patients. In the remaining 2 patients, the D/P ratios of Cr on PET and of Cr, β2M, albumin, IgG, and α2M in overnight effluent, and the FDP and IL-6 levels in overnight effluent were markedly elevated after the switching from glucose to icodextrin PDF, and they remained high after the switch back to glucose PDF. One of these 2 patients developed pre-EPS and was treated with prednisolone and concomitant hemodialysis. The other was switched from peritoneal dialysis to hemodialysis. ⋄ Conclusions Icodextrin dialysis solution may induce an inflammatory reaction in the peritoneum. Further investigation is necessary for the long-term use of icodextrin PDF.
Collapse
|
15
|
Moriishi M, Kawanishi H, Shintaku S, Tsuchiya S. P1195ASSESSMENT OF BODY FLUID VOLUME USING THE BIOIMPEDANCE METHOD IN PERITONEAL DIALYSIS PATIENTS. Nephrol Dial Transplant 2020. [DOI: 10.1093/ndt/gfaa142.p1195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background and Aims
ppropriate maintenance of body fluid balance in peritoneal dialysis (PD) patients is important for the amelioration of cardiovascular complications and prognosis. In recent years, the usefulness of body fluid measurement with the bioimpedance method in PD patients has been reported. Meanwhile, peritoneal permeability plays an important role in maintaining body fluid balance in PD patients. In the present study, we examined the correlation between peritoneal permeability and body fluid volume in PD patients.
Method
A total of 58 patients who were undergoing PD at our hospital (42 men and 16 women; mean age, 68 ± 16.2 years; mean dialysis history, 63.5 ± 144.9 months; 25 DM and 35 non-DM patients). Overhydration (OH), total body water (TBW) volume, extracellular water (ECW) volume, and lean tissue mass (LTM) were measured using a body composition analyzer (BCM Fresenius Medical Care Japan). At the same time, peritoneal permeability was measured with fast peritoneal equilibration test to determine the dialysate-to-plasma ratio for creatinine (D/P-Cr), and its correlations with sex, age, age at the time of introduction of dialysis, dialysis history, diabetes history, brain natriuretic peptide (BNP) level, high-sensitivity troponin I (hsTnI) level, blood pressure, body weight, residual kidney function, and ultrafiltration were examined.
Results
The mean OH was 2.53 ± 2.44 L, and 8 patients (13.8%) had an OH of ≤1.1 L. The results of the multivariate analysis revealed that OH positively correlated with the presence or absence of diabetes, ultrafiltration, D/P-Cr, BNP level, hsTnI level, TBW, and ECW, but showed no correlation with sex, dialysis history, age, age at the time of introduction of dialysis, residual renal function, or LTM. Furthermore, the subjects were assigned to D/P-Cr ≥ 0.65 and ≤0.65 groups. In the former, OH correlated with diabetes and male sex by being negatively correlated with age and age at the time of introduction of dialysis and positively correlated with BNP level, hsTnI level, TBW, and ECW. However, in the D/P-Cr ≤ 0.65 group, OH positively correlated with BNP level and ECW.
Conclusion
Our results suggest that youth, complications of DM, and men are at risk for fluid overload in PD patients with increased peritoneal permeability.
Collapse
Affiliation(s)
- Misaki Moriishi
- Tsuchiya general hospital, internal medicine, Hiroshima, Japan
| | | | | | | |
Collapse
|
16
|
Matsubara M, Banshodani M, Takahashi A, Kawai Y, Saiki T, Yamashita M, Shiraki N, Shintaku S, Moriishi M, Masaki T, Kawanishi H. Vascular access management after percutaneous transluminal angioplasty using a calcium alginate sheet: a randomized controlled trial. Nephrol Dial Transplant 2020; 34:1592-1596. [PMID: 29846686 DOI: 10.1093/ndt/gfy143] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Management of vascular access (VA) is essential in hemodialysis (HD) patients. However, VA often fails and percutaneous transluminal angioplasty (PTA) is required. Conventional hemostasis at the puncture site is associated with complications. This study aimed to analyze the efficacy and safety of a hemostatic wound dressing made of calcium alginate at the puncture site of VA after PTA and evaluate other factors affecting hemostasis. METHODS After PTA for VA, 200 HD patients were randomized to a calcium alginate sheet (CA) group (n = 100) or a no drug-eluting sheet (control) group (n = 100). We recorded time to hemostasis at the puncture site every 5 min, noting any complications. RESULTS In the CA group, rates of hemostatic achievement at 5, 10, 15 and >15 min were 57, 25, 8 and 10%, respectively. In the control group, the rates were 39, 28, 14 and 19%, respectively. Rates of hemostatic achievement at 5 min were significantly higher in the CA group (P = 0.01). In logistic regression analysis, factors affecting hemostasis within 5 min were use of the CA sheet [odds ratio (OR) 2.33; 95% confidence interval (CI) 1.26-4.37], platelet count ≤100 000/μL (OR 0.19; 95% CI 0.04-0.69), number of antithrombotic tablets used per day ≥1 tablet (OR 0.50; 95% CI 0.26-0.94) and upper arm VA (OR 0.16; 95% CI 0.03-0.55). CONCLUSIONS A CA sheet can safely reduce time to hemostasis at the puncture site after PTA, and should be considered for treating patients with a bleeding tendency.
Collapse
Affiliation(s)
- Makoto Matsubara
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Masataka Banshodani
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Akira Takahashi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Yusuke Kawai
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Tomoki Saiki
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Masahiro Yamashita
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Nobuaki Shiraki
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Sadanori Shintaku
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Misaki Moriishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Takao Masaki
- Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan
| | - Hideki Kawanishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan.,Department of Transplant Surgery, Hiroshima University Hospital, Hiroshima, Japan
| |
Collapse
|
17
|
Abstract
Since the first peritoneal dialysis (PD) patients with encapsulating peritoneal sclerosis (EPS) were reported in 1980, EPS has been considered primarily a fatal complication. The incidence of EPS in PD patients has been reported to range from 0.7% to 7.3%, and the rate appears to be higher in patients receiving long-term treatment. The most recent data from Japan show an overall incidence of 2.5%, with a clear impact of extended PD duration, which also augments mortality. The incidence increases and the prognosis worsens with longer durations of PD. The incidences (and mortality rates) for EPS were 0% (0%), 0.7% (0%), 2.1% (8.3%), 5.9% (28.6%), 5.8% (61.5%), and 17.2% (100%) for patients who had undergone PD for 3, 5, 8, 10, 15, and >15 years respectively. Because EPS occurs after withdrawal from PD in more than half of patients with the condition, strict monitoring is necessary when a long-term patient is withdrawn from PD. Maintaining patients on standard PD for more than 8 years using conventional solutions is associated with a substantial risk for the development of EPS.
Collapse
Affiliation(s)
| | - Misaki Moriishi
- Akane Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| |
Collapse
|
18
|
Abstract
♦ Background Encapsulating peritoneal sclerosis (EPS) is a serious complication of long-term peritoneal dialysis (PD). The mortality rate for EPS has been high, primarily because of complications related to bowel obstruction. Also, therapeutic guidelines for EPS have not yet been established. In our hospital, favorable postoperative results were obtained in 50 patients whose EPS was treated surgically. ♦ Patients All patients had chronic glomerulonephritis as the underlying kidney disease. All had undergone PD for between 29 months and 220 months (average: 113.9 months). During the course of PD, 3 patients developed EPS and were subsequently transferred to hemodialysis (HD). The other 47 patients (94.0%) developed EPS after discontinuation of PD. The reasons for transfer to HD were inadequate ultrafiltration (26 patients), bacterial peritonitis (16 patients), hypoalbuminemia (2 patients), renal transplantation (3 patients), and occurrence of EPS (3 patients). ♦ Intervention At laparotomy, a definitive diagnosis of EPS was established in all patients by the presence of clumped intestine cocooned with a dense sclerotic membrane. In all cases, the small intestine was completely released by ablation of the capsules, resulting in resolution of the bowel obstruction symptoms. In 5 patients, the large intestine was ablated solely at the region of the sigmoid colon. The operating time varied from 3 hours to 18 hours (average: 6.9 hours). Oral food intake was initiated 5 – 60 days (average: 10.2 days) after surgery. ♦ Results Perforation of the small intestine was detected postoperatively in 2 patients, who died 26 days and 37 days after surgery. The remaining 48 patients were followed for between 9 months and 107 months (average: 34.6 months). During follow-up, 6 – 12 months after the initial surgery, 4 patients experienced a recurrence of bowel obstruction symptoms that required a second laparotomy with enterolysis. Excluding the 2 patients with fatal outcomes, 46 patients (96%) experienced complete relief from bowel obstruction symptoms. The remaining 2 patients continued to experience mild, sub-acute bowel obstruction symptoms that could be successfully controlled solely by diet. ♦ Conclusions Surgical treatment of 50 patients with EPS produced successful outcomes in all but 2 patients (96% success). Encapsulating peritoneal sclerosis should be actively treated by surgeons who genuinely understand this pathologic condition.
Collapse
Affiliation(s)
| | | | - Misaki Moriishi
- Akane Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | | |
Collapse
|
19
|
Arata R, Banshodani M, Yamashita M, Shintaku S, Moriishi M, Kawanishi H. Perforative peritonitis confused with peritoneal dialysis-related peritonitis: Report of three cases. Int J Surg Case Rep 2020; 70:20-23. [PMID: 32361606 PMCID: PMC7193318 DOI: 10.1016/j.ijscr.2020.03.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Revised: 03/11/2020] [Accepted: 03/16/2020] [Indexed: 11/30/2022] Open
Abstract
Intestinal perforation in patients on peritonitis dialysis (PD) has high mortality. Perforative peritonitis in PD patients and PD-associated peritonitis patients have similar signs. Rapid diagnosis can help exclude perforation in cases of refractory peritonitis.
Introduction Perforative peritonitis in patients on peritoneal dialysis (PD) is a serious adverse event associated with significant mortality. The signs and symptoms of perforative peritonitis in patients on PD are often confused with those of PD-related peritonitis; therefore, early diagnosis is often difficult. Presentation of cases In all three cases, antibiotic therapy was started for peritonitis. Although contrast-enhanced computed tomography (CT) was not performed, perforative peritonitis was suspected due to severe cloudiness of PD effluents, and emergency surgeries were performed 8, 5, and 6 days after therapy onset in cases 1, 2, and 3, respectively. In case 1, the ileum was perforated owing to ischemia, and partial ileal resection and divided ileostomy were performed. The patient died 18 days postoperatively. In case 2, partial ileal resection and divided ileostomy were performed for an incarcerated obturator hernia and perforated ileum. The patient was transferred for hemodialysis (HD) and discharged 117 days postoperatively. In case 3, lavage drainage was performed for peritonitis because of mesenteric penetration of a sigmoid colon diverticulum. The patient was then transferred for HD, and colostomy was subsequently performed. He was discharged 159 days postoperatively. Discussion Early diagnosis between PD-related peritonitis and perforative peritonitis is often difficult since the washing effect of the peritoneal dialysate might relieve peritoneal irritation. Conclusion In PD patients with refractory peritonitis, it is necessary to keep in mind the possibility of perforative peritonitis, and the differential diagnosis should be performed using contrast-enhanced CT within at least 5 days after antibiotic therapy.
Collapse
Affiliation(s)
- Ryosuke Arata
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Japan.
| | - Masataka Banshodani
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Japan.
| | - Masahiro Yamashita
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Japan
| | - Sadanori Shintaku
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Japan
| | - Misaki Moriishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Japan
| | - Hideki Kawanishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Japan
| |
Collapse
|
20
|
Banshodani M, Kawanishi H, Moriishi M, Shintaku S, Tsuchiya S. Association between Dialysis Modality and Cardiovascular Diseases: A Comparison between Peritoneal Dialysis and Hemodialysis. Blood Purif 2019; 49:302-309. [PMID: 31851981 DOI: 10.1159/000504040] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Accepted: 10/10/2019] [Indexed: 11/19/2022]
Abstract
INTRODUCTION In patients with end-stage kidney disease (ESKD), cardiovascular diseases (CVDs) are the most common causes of hospitalization and death. OBJECTIVE We aimed to determine the association between dialysis modality and CVDs. METHODS This retrospective observational cohort study compared the emergency hospitalization and mortality of patients with CVDs who underwent peritoneal dialysis (PD) versus hemodialysis (HD). After propensity score matching, the risk factors were evaluated using Cox proportional hazards regression models. RESULTS A total of 260 patients were matched: 130 of 135 PD (75 men; age, 65.4 years; dialysis vintage, 3.3 years) and 130 of 706 HD (70 men [p = 0.5]; 66.6 years [p = 0.4]; dialysis vintage, 3.1 years [p = 0.5]) patients. Emergency hospitalization rates (hospitalizations/person-years) for overall CVDs (0.138 vs. 0.066, p = 0.002) and pulmonary edema (0.048 vs. 0.019, p = 0.03) were significantly higher in patients who underwent PD than those who underwent HD. The log-rank test revealed that all-cause and CVD mortalities were significantly higher in PD (both p < 0.001). Mortality rates (deaths/person-years) for overall CVDs (0.058 vs. 0.015, p < 0.002), cerebrovascular disease (0.019 vs. 0.004, p = 0.03), and ischemic heart disease (0.010 vs. 0, p = 0.02) were significantly higher in PD. The Cox proportional hazards regression model showed that PD and age were significant predictors of emergency hospitalization (hazard ratio [HR] 2.70; 95% CI 1.53-4.77; p = 0.001) and mortality (HR 4.41; 95% CI 1.66-11.72; p = 0.003) for CVDs. CONCLUSIONS PD is a risk factor for emergency hospitalization and mortality associated with CVDs in dialysis patients with ESKD. Strict control of body fluid balance may prevent cardiovascular events in patients undergoing PD.
Collapse
Affiliation(s)
- Masataka Banshodani
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan,
| | - Hideki Kawanishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Misaki Moriishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Sadanori Shintaku
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Shinichiro Tsuchiya
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| |
Collapse
|
21
|
Moriishi M, Hideki K, Sadanori S, Shinichiro T. SP643Changes in peritoneal solute transport with low GDP peritoneal dialysis solution. Nephrol Dial Transplant 2019. [DOI: 10.1093/ndt/gfz103.sp643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Kawai Y, Banshodani M, Moriishi M, Sato T, Shintaku S, Masaki T, Kawanishi H. Iliopsoas Abscess in Hemodialysis Patients With End-Stage Kidney Disease. Ther Apher Dial 2019; 23:534-541. [PMID: 30864296 DOI: 10.1111/1744-9987.12801] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2018] [Revised: 01/29/2019] [Accepted: 03/11/2019] [Indexed: 11/27/2022]
Abstract
Iliopsoas abscess in HD patients is rare. We examined nine HD patients with iliopsoas abscess (six men and five diabetes mellitus cases) treated between 2005 and 2015. Mean age and dialysis vintage at onset were 72 years and 109 months, respectively. Of the nine patients, four had lumbar orthopedic diseases, and two had all components of the classic triad of iliopsoas abscess at onset. All nine patients underwent percutaneous drainage, while seven underwent antimicrobial therapy. The most common pathogenic bacterium was methicillin-resistantStaphylococcus aureus(MRSA) (n = 5). Four patients had multilocular recurrence on the same side as the initial abscess and did not undergo CT before drainage catheter removal. Five patients died in the hospital, in which three died due to infectious diseases by MRSA. We suggest percutaneous drainage as the first-line therapy for HD patients with iliopsoas abscess and recommend combining antimicrobial therapy for MRSA, because of poor prognosis.
Collapse
Affiliation(s)
- Yusuke Kawai
- Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Masataka Banshodani
- Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Misaki Moriishi
- Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Tomoyasu Sato
- Radiology, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Sadanori Shintaku
- Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Takao Masaki
- Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan
| | - Hideki Kawanishi
- Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| |
Collapse
|
23
|
Banshodani M, Kawanishi H, Moriishi M, Shintaku S, Tsuchiya S. Impact of Hybrid Therapy Comprising Peritoneal Dialysis and Hemodialysis on Acute Cardiovascular Events. Blood Purif 2018; 47:330-336. [PMID: 30522124 DOI: 10.1159/000495357] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2018] [Accepted: 11/12/2018] [Indexed: 11/19/2022]
Abstract
BACKGROUND The impact of hybrid therapy comprising peritoneal dialysis (PD) and hemodialysis on cardiovascular events in PD patients remains unclear. OBJECTIVE We aimed to evaluate the effect of hybrid therapy on cardiovascular events. METHODS A total of 93 PD patients undergoing hybrid therapy for ≥3 years were divided into 2 groups according to left ventricular ejection fraction (LVEF): lower ejection fraction (LEF [n = 29], LVEF < 60%) and normal ejection fraction (NEF [n = 64], LVEF ≥60%). Hospitalization rates and echocardiographic parameters were evaluated. RESULTS The 1-year hospitalization rate for acute cardiovascular events decreased after the therapy initiation in both groups (LEF: 0.36-0.11, p = 0.02 and NEF: 0.43-0.06, p < 0.001). In generalized linear mixed models, LVEF (44 ± 15%) improved at 1, 2, and 3 years after initiation (53 ± 18, 55 ± 17, and 58 ± 7%; p < 0.05) in the LEF group, whereas, in the NEF group, LVEF (68 ± 5%) was maintained at 1, 2, and 3 years after initiation (67 ± 8, 67 ± 9, and 68 ± 9%; p > 0.05). Mitral inflow E velocity to tissue Doppler e' ratio was maintained at the same level at 1-3 years after initiation in both groups. Left ventricular mass index (LVMI; 189 ± 41 g/m2) was decreased at 1 (178 ± 35 g/m2; p = 0.8), 2 (160 ± 45 g/m2; p = 0.008), and 3 (166 ± 47 g/m2; p = 0.05) years after initiation in the LEF group, whereas in the NEF group, LVMI (157 ± 45 g/m2) was maintained at 1, 2, and 3 years after initiation (153 ± 40, 155 ± 54, and 158 ± 52 g/m2; p > 0.05). CONCLUSION Hybrid therapy decreased acute cardiovascular events and improved systolic cardiac function in PD patients in the LEF group.
Collapse
Affiliation(s)
- Masataka Banshodani
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan,
| | - Hideki Kawanishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Misaki Moriishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Sadanori Shintaku
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Shinichiro Tsuchiya
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| |
Collapse
|
24
|
Banshodani M, Kawanishi H, Moriishi M, Shintaku S, Tsuchiya S. Increased Frequency of In-Center Hemodialysis as Rescue Therapy: Impact on Hospitalization for Acute Cardiovascular Events. Blood Purif 2018; 47:377-384. [PMID: 30466077 DOI: 10.1159/000495023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Accepted: 10/30/2018] [Indexed: 11/19/2022]
Abstract
BACKGROUND The intermittency of conventional hemodialysis (HD) leads to an increase in cardiovascular events. OBJECTIVE We aimed to evaluate the effect of in-center frequent HD (FHD, 4-6 times a week) as a rescue option for cardiovascular events. METHOD Patients who failed to achieve fluid volume control with conventional HD (thrice a week) were administered FHD. A total of 52 patients were divided into 2 groups by left ventricular ejection fraction (LVEF): low ejection fraction (LEF [n = 26], LVEF < 55%) and normal ejection fraction (NEF [n = 26], LVEF ≥55%). Mortality and hospitalization rates were evaluated. RESULTS All-cause mortality tended to be higher in the LEF than in the NEF group (p = 0.09). The 1-year hospitalization rate for acute cardiovascular events decreased in both LEF (1.24-0.89; p = 0.049) and NEF (0.36-0.16; p = 0.01) groups. In Cox regression models, LVEF < 55% (hazard ratio 3.81; 95% CI 1.15-12.66; p = 0.03) was identified as the risk factor for hospitalization for acute cardiovascular events. CONCLUSION In-center FHD may decrease acute cardiovascular events.
Collapse
Affiliation(s)
- Masataka Banshodani
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan,
| | - Hideki Kawanishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan.,Faculty of Medicine, Hiroshima University, Hiroshima, Japan
| | - Misaki Moriishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Sadanori Shintaku
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Shinichiro Tsuchiya
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| |
Collapse
|
25
|
Takahashi N, Yoshizawa T, Okubo A, Kumagai J, Kawanishi H, Tsuchiya S, Moriishi M, Masaki T, Ebata T. Usefulness of the Japanese version of the 5-D itch scale for rating pruritus experienced by patients undergoing hemodialysis. Ren Replace Ther 2018. [DOI: 10.1186/s41100-018-0167-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
26
|
Shintaku S, Sato T, Kawanishi H, Moriishi M, Tsuchiya S. The efficacy of drug-eluting stent for recurrent central venous restenosis in a patient undergoing hemodialysis. J Vasc Access 2018; 20:76-79. [DOI: 10.1177/1129729818763473] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Introduction: Recurrent central venous restenosis is problematic in patients with ipsilateral arteriovenous fistula. We report our experience using a drug-eluting stent for the treatment of recurrent central vein restenosis. Case report: A 60-year-old man consulted our hospital because of recurrent swelling of his left upper limb with radial-cephalic arteriovenous fistula that originated in the distal forearm. More than 3 years prior, two bare-metal stents were placed for the obstructed lesions in the left subclavian and brachiocephalic venous lesions, and repeated balloon angioplasty for recurrent in-stent stenosis was performed approximately every 3 months. Angiography with iodinated contrast agents revealed an approximately 3-cm-long restenosis at the distal part of the bare-metal stents. One drug-eluting stent (Zilver PTX Drug-Eluting Peripheral Stent; Cook Medical, Bloomington, IN, USA) was deployed at the narrowing lesion, followed by balloon angioplasty. The stenotic lesion was successfully and safely dilated. The patient consulted our hospital 5.5 months after drug-eluting stent placement because of restenosis at the distal part of the drug-eluting stent, but only in a shorter segment than before. Freedom from clinically driven target-lesion revascularization (TLR) extended from 3.1 to 5.5 months after drug-eluting stent placement. Although additional implantation of the second drug-eluting stent was required 14.6 months after the first drug-eluting stent placement, freedom from TLR before/after the second drug-eluting stent placement extended from 4.4 months to more than 8.6 months. Conclusion: Drug-eluting stent placement is an effective strategy for recurrent central venous stenosis in patients with ipsilateral arteriovenous fistula. To our knowledge, this is the first report of drug-eluting stent placement for recurrent venous stenosis in a patient undergoing hemodialysis.
Collapse
Affiliation(s)
- Sadanori Shintaku
- Department of Artificial Organs, Tsuchiya General Hospital, Hiroshima, Japan
| | - Tomoyasu Sato
- Department of Radiology, Tsuchiya General Hospital, Hiroshima, Japan
| | - Hideki Kawanishi
- Department of Artificial Organs, Tsuchiya General Hospital, Hiroshima, Japan
- Faculty of Medicine, Hiroshima University, Hiroshima, Japan
| | - Misaki Moriishi
- Department of Artificial Organs, Tsuchiya General Hospital, Hiroshima, Japan
| | - Shinichiro Tsuchiya
- Department of Artificial Organs, Tsuchiya General Hospital, Hiroshima, Japan
| |
Collapse
|
27
|
Banshodani M, Kawanishi H, Shintaku S, Yamashita M, Moriishi M, Tsuchiya S. Effective Remedy for Encapsulating Peritoneal Sclerosis with Ureteroileal Fistula. Perit Dial Int 2017; 37:648-649. [PMID: 29123001 DOI: 10.3747/pdi.2017.00074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Encapsulating peritoneal sclerosis (EPS), treated with surgical enterolysis as a final option, may become refractory to surgical intervention due to intraperitoneal complications. We report the case of a 59-year-old man presenting with EPS who underwent enterolysis at the age of 50, following 15 years of peritoneal dialysis (PD) and peritonitis. During the patient's first surgery, complete surgical enterolysis could not be performed due to severe intestinal adhesions with a deteriorated/calcified small bowel. Six months after the surgery, the obstructive bowel symptoms occurred several times a year. Nine years later, the patient suffered cystitis-like symptoms and fecal discharge from the urinary meatus. The patient was subsequently diagnosed with EPS recurrence with ureteroileal fistula between the right ureter and ileum. During the second surgical intervention, we conducted a divided jejunostomy, as surgical enterolysis and fistulectomy were unachievable due to severe ileal adhesion with calcified capsule and inflammation. Thereafter, symptoms reduced dramatically and oral intake became possible. Three years following surgery, the patient's condition is improved, with no evidence of EPS recurrence or cystitis-like symptoms. Although EPS with ureteroileal fistula is extremely rare, we propose that jejunostomy may be an effective treatment option for patients with EPS refractory to surgical enterolysis or intestinal bypass due to intraperitoneal complications.
Collapse
Affiliation(s)
- Masataka Banshodani
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, 3-30 Nakajimacho, Naka-ku, Hiroshima, 730-8655, Japan
| | - Hideki Kawanishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, 3-30 Nakajimacho, Naka-ku, Hiroshima, 730-8655, Japan.,Faculty of Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan
| | - Sadanori Shintaku
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, 3-30 Nakajimacho, Naka-ku, Hiroshima, 730-8655, Japan
| | - Masahiro Yamashita
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, 3-30 Nakajimacho, Naka-ku, Hiroshima, 730-8655, Japan
| | - Misaki Moriishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, 3-30 Nakajimacho, Naka-ku, Hiroshima, 730-8655, Japan
| | - Shinichiro Tsuchiya
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, 3-30 Nakajimacho, Naka-ku, Hiroshima, 730-8655, Japan
| |
Collapse
|
28
|
Banshodani M, Kawanishi H, Fukuma S, Moriishi M, Shintaku S, Tsuchiya S. The impact of hemodialysis schedules on the day of the week of hospitalization for cardiovascular and infectious diseases, over a period of 20 years. PLoS One 2017; 12:e0180577. [PMID: 28700621 PMCID: PMC5503277 DOI: 10.1371/journal.pone.0180577] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2017] [Accepted: 06/16/2017] [Indexed: 01/11/2023] Open
Abstract
There have been no studies as yet that have evaluated how hemodialysis (HD) schedules affect the day of the week of hospitalization for cardiovascular diseases (CVDs) and infectious diseases (IDs), over a period of time. Herein, we performed a retrospective observational cohort study (1995–2014) evaluating 11,111 hospitalizations in 1,953 patients with end-stage renal disease, receiving HD 3 times a week (following either a Monday-Wednesday-Friday [MWF] schedule or a Tuesday-Thursday-Saturday [TTS] schedule) or receiving frequent HD (FHD) at least 4 times a week. Overall, hospitalization rates for CVDs and IDs were the highest on Monday in the MWF schedule and Tuesday in the TTS schedule compared to the average rates for all the days of the week. When generalized estimating equations (GEEs) were used in conjunction with robust variance estimators of each type of CVD, the risk for pulmonary edema was found to be significantly higher on Sunday and Monday in the MWF schedule and Monday and Tuesday in the TTS schedule. For both cerebrovascular and ischemic heart disease, the risks were significantly higher on Tuesday in the MWF schedule and Wednesday in the TTS schedule. Moreover, there were significant differences in the day of the week risks among the various CVD types. On trend analysis, the overall hospitalization rate for CVDs on the first HD day did not decrease (P = 0.2); however, the hospitalization rate for IDs on the first HD day significantly decreased (P = 0.02) over a span of 20 years. When GEEs were used in the case of FHD patients with severe heart failure, the hospitalization rate on the first HD day (Monday) significantly decreased after FHD initiation (P = 0.04). It was found that HD schedules affected the day of the week of hospitalization for CVDs. FHD may lower the day of the week risk.
Collapse
Affiliation(s)
- Masataka Banshodani
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Hideki Kawanishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
- Faculty of Medicine, Hiroshima University, Hiroshima, Japan
- * E-mail:
| | - Shingo Fukuma
- Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Misaki Moriishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Sadanori Shintaku
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Shinichiro Tsuchiya
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| |
Collapse
|
29
|
Banshodani M, Kawanishi H, Moriishi M, Shintaku S, Hashimoto S, Nishihara M. Inguinal hernia in hemodialysis versus peritoneal dialysis patients: a case-control study. Ren Replace Ther 2016. [DOI: 10.1186/s41100-016-0035-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
30
|
Kawakami Y, Imamura M, Ikeda H, Suzuki M, Arataki K, Moriishi M, Mori N, Kokoroishi K, Katamura Y, Ezaki T, Ueno T, Ide K, Masaki T, Ohdan H, Chayama K. Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study. J Viral Hepat 2016; 23:850-856. [PMID: 27346670 DOI: 10.1111/jvh.12553] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Accepted: 04/26/2016] [Indexed: 12/23/2022]
Abstract
The aim of this study was to evaluate the pharmacokinetic profile of daclatasvir (DCV) and asunaprevir (ASV) dual therapy in haemodialysis patients infected with hepatitis C virus (HCV). Eighteen haemodialysis patients and 54 patients with normal renal function were treated with DCV and ASV dual therapy for 24 weeks. We evaluated the pharmacokinetic profiles of DCV and ASV and examined the rate of sustained virological response 12 weeks after the end of treatment (SVR12 ) and incidence of adverse events during treatment of haemodialysis patients infected with chronic HCV genotype 1 infection. To adjust for potential differences in baseline characteristics between haemodialysis patients and patients with normal renal function, we used propensity scores case-control matching methods. Area under the plasma concentration time curve from 0 to 6 h (AUC0-6 h ) of DCV was slightly lower in haemodialysis patients than in patients with normal renal function (P > 0.6). AUC0-6 h of ASV was significantly lower in haemodialysis patients (P = 0.012). SVR12 rates were 100% (18/18) for haemodialysis and 96.2% (52/54) for patients with normal renal function. Changes in mean log10 HCV RNA levels and viral response were higher in haemodialysis patients compared to patients with normal renal function. No discontinuations due to adverse events occurred. In conclusion, DCV and ASV dual therapy for HCV infection is effective and safe with similar results in haemodialysis patients compared to patients with normal renal function.
Collapse
Affiliation(s)
- Y Kawakami
- Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.,Liver Research Project Center, Hiroshima University, Hiroshima, Japan
| | - M Imamura
- Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.,Liver Research Project Center, Hiroshima University, Hiroshima, Japan
| | - H Ikeda
- Division of Gastroenterology and Hepatology, St. Marianna University School of Medicine, Kanagawa, Japan
| | - M Suzuki
- Division of Gastroenterology and Hepatology, St. Marianna University School of Medicine, Kanagawa, Japan
| | - K Arataki
- Tsuchiya General Hospital, Hiroshima, Japan
| | - M Moriishi
- Tsuchiya General Hospital, Hiroshima, Japan
| | - N Mori
- Department of Gastroenterology/Liver Center, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan
| | - K Kokoroishi
- Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan
| | - Y Katamura
- Department of Gastroenterology, Onomichi General Hospital, Hiroshima, Japan
| | - T Ezaki
- Department of Nephrology, Onomichi General Hospital, Hiroshima, Japan
| | - T Ueno
- Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan
| | - K Ide
- Department of Surgery, Division of Frontier Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
| | - T Masaki
- Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan
| | - H Ohdan
- Department of Surgery, Division of Frontier Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
| | - K Chayama
- Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan. .,Liver Research Project Center, Hiroshima University, Hiroshima, Japan. .,Laboratory for Digestive Diseases, RIKEN Center for Integrative Medical Sciences, The Institute of Physical and Chemical Research (RIKEN), Hiroshima, Japan.
| |
Collapse
|
31
|
Hasegawa T, Nakai S, Moriishi M, Ito Y, Itami N, Masakane I, Hanafusa N, Taniguchi M, Hamano T, Shoji T, Yamagata K, Shinoda T, Kazama J, Watanabe Y, Shigematsu T, Marubayashi S, Morita O, Wada A, Hashimoto S, Suzuki K, Kimata N, Wakai K, Fujii N, Ogata S, Tsuchida K, Nishi H, Iseki K, Tsubakihara Y, Nakamoto H. Peritoneal Dialysis Registry With 2012 Survey Report. Ther Apher Dial 2016; 19:529-39. [PMID: 26768809 DOI: 10.1111/1744-9987.12382] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Since 2009, the peritoneal dialysis (PD) registry survey has been carried out as part of the annual nationwide survey conducted by the Statistical Survey Committee of the Japanese Society for Dialysis Therapy with the cooperation of the Japanese Society for Peritoneal Dialysis. In this report, the current status of PD patients is presented on the basis of the results of the survey conducted at the end of 2012. The subjects were PD patients who lived in Japan and participated in the 2012 survey. Descriptive analysis of various items was performed, which included the current status of the combined use of PD and another dialysis method such as hemodialysis (HD) or hemodiafiltration (HDF), the method of exchanging dialysate, the use of an automated peritoneal dialysis (APD) machine, and the rates of peritonitis and catheter exit-site infection. From the results of the facility survey in 2012, the number of PD patients was 9514, a decrease of 128 from 2011. Among the entire dialysis patient population, 3.1% were PD patients, a decrease of 0.1%. Among the studied patients, 347 had a peritoneal catheter and underwent peritoneal lavage, 175 were started on PD in 2012 but introduced to other blood purification methods in the same year, and 1932 underwent both PD and another dialysis method such as HD or HDF. The percentage of patients who underwent PD and another dialysis method increased with PD vintage: <1 year, 4.8%; 1 to <2 years, 9.2%; 2 to <4 years, 16.3%; 4 to <8 years, 32.0%; and ≥8 years, 47.5%. The percentage of PD patients who completely manually exchanged the dialysate was 29.8%. The percentages of PD patients who used a double-bag exchange system with ultraviolet-light irradiation and those who used the same system but with a sterile connecting device were 54.7 and 13.9%, respectively. The percentage of patients on PD for <1 year using an APD machine was 43.4%, and it decreased with a PD vintage of ≥2 years. The mean rate of peritonitis was 0.22 per patient per year. The mean rate of catheter exit-site infections was 0.36 per patient per year.
Collapse
Affiliation(s)
- Takeshi Hasegawa
- Subcommittee of PD Registry, Statistical Survey Committee, Japanese Society for Dialysis Therapy.,Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Shigeru Nakai
- Subcommittee of PD Registry, Statistical Survey Committee, Japanese Society for Dialysis Therapy.,Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Misaki Moriishi
- Subcommittee of PD Registry, Statistical Survey Committee, Japanese Society for Dialysis Therapy
| | - Yasuhiko Ito
- Subcommittee of PD Registry, Statistical Survey Committee, Japanese Society for Dialysis Therapy
| | - Noritomo Itami
- Subcommittee of PD Registry, Statistical Survey Committee, Japanese Society for Dialysis Therapy.,Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Ikuto Masakane
- Subcommittee of PD Registry, Statistical Survey Committee, Japanese Society for Dialysis Therapy.,Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Norio Hanafusa
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Masatomo Taniguchi
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Takayuki Hamano
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Tetsuo Shoji
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Kunihiro Yamagata
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Toshio Shinoda
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Junichiro Kazama
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Yuzo Watanabe
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Takashi Shigematsu
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Seiji Marubayashi
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Osamu Morita
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Atsushi Wada
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Seiji Hashimoto
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Kazuyuki Suzuki
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Naoki Kimata
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Kenji Wakai
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Naohiko Fujii
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Satoshi Ogata
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Kenji Tsuchida
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Hiroshi Nishi
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Kunitoshi Iseki
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Yoshiharu Tsubakihara
- Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| | - Hidetomo Nakamoto
- Subcommittee of PD Registry, Statistical Survey Committee, Japanese Society for Dialysis Therapy.,Subcommittee of Statistical Analysis, Statistical Survey Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
| |
Collapse
|
32
|
Banshodani M, Kawanishi H, Moriishi M, Shintaku S, Hashimoto S, Tsuchiya S. Percutaneous Endoscopic Gastrostomy with Jejunal Extension for an Encapsulating Peritoneal Sclerosis Refractory to Surgical Enterolysis. Perit Dial Int 2016; 36:562-3. [PMID: 27659928 DOI: 10.3747/pdi.2015.00260] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Surgical enterolysis is the final option for patients with encapsulating peritoneal sclerosis (EPS). However, EPS is sometimes refractory to surgical enterolysis. This is the first report of successful use of percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) in a patient with EPS that was refractory to surgical enterolysis. We propose that sustained drainage of digestive juices by PEG-J, along with central venous nourishment at home, can be a treatment option for patients with EPS that cannot be treated with radical measures.
Collapse
Affiliation(s)
- Masataka Banshodani
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Hideki Kawanishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan Faculty of Medicine, Hiroshima University, Hiroshima, Japan
| | - Misaki Moriishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Sadanori Shintaku
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Shinji Hashimoto
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Shinichiro Tsuchiya
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| |
Collapse
|
33
|
Ago R, Shindo T, Banshodani M, Shintaku S, Moriishi M, Masaki T, Kawanishi H. Hypomagnesemia as a predictor of mortality in hemodialysis patients and the role of proton pump inhibitors: A cross-sectional, 1-year, retrospective cohort study. Hemodial Int 2016; 20:580-588. [PMID: 27329549 DOI: 10.1111/hdi.12437] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2016] [Revised: 04/10/2016] [Indexed: 11/29/2022]
Abstract
Introduction This study aimed to evaluate the association between proton pump inhibitor (PPI) use and serum magnesium levels, and the role of hypomagnesemia and PPI use as a risk factor for mortality in hemodialysis patients. Methods An observational study, including a cross-sectional and 1-year retrospective cohort study. The study comprised 399 hemodialysis patients at a single center, and was conducted from January to September 2014. Multiple linear regression analysis was used to investigate the independent relationship between serum magnesium levels and baseline demographic and clinical variables, including PPI and histamine-2 receptor antagonist use. Cox regression model was used to identify lower serum magnesium level and PPI as a predictor of 1-year mortality. Findings Serum magnesium levels were lower with PPI use than non-PPI use (2.39 ± 0.36 vs. 2.56 ± 0.39 mg/dL, P < 0.001). Multiple linear regression analysis showed that PPI use, low serum albumin levels, and low serum potassium and high-sensitivity C-reactive protein (hs-CRP) levels were significantly associated with low serum magnesium levels. A total of 29 deaths occurred during the follow-up period. According to Cox regression analysis stratified by hs-CRP, only high serum hs-CRP levels (>4.04 mg/L) in association with low serum magnesium levels was an independent risk factor for 1-year mortality (hazard ratio: 2.92; 95% CI: 1.53-6.40, P < 0.001). Discussion Serum magnesium levels are lower in PPI use. In the inflammatory state, a low serum magnesium level is a significant predictor of mortality in hemodialysis patients.
Collapse
Affiliation(s)
- Rika Ago
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, 3-30 Nakajimacho, Naka-ku, Hiroshima, 730-8655, Japan. .,Department of Nephrology, Miyoshi Central Hospital, 531 Higashisakeya-cho, Miyoshi, Hiroshima, 728-8502, Japan.
| | - Toshihiro Shindo
- Department of Nephrology, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan
| | - Masataka Banshodani
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, 3-30 Nakajimacho, Naka-ku, Hiroshima, 730-8655, Japan
| | - Sadanori Shintaku
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, 3-30 Nakajimacho, Naka-ku, Hiroshima, 730-8655, Japan
| | - Misaki Moriishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, 3-30 Nakajimacho, Naka-ku, Hiroshima, 730-8655, Japan
| | - Takao Masaki
- Department of Nephrology, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan
| | - Hideki Kawanishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, 3-30 Nakajimacho, Naka-ku, Hiroshima, 730-8655, Japan.,Faculty of Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan
| |
Collapse
|
34
|
Takahashi N, Yoshizawa T, Kumagai J, Kawanishi H, Moriishi M, Masaki T, Tsuchiya S. Response of patients with hemodialysis-associated pruritus to new treatment algorithm with nalfurafine hydrochloride: a retrospective survey-based study. Ren Replace Ther 2016. [DOI: 10.1186/s41100-016-0039-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
35
|
Kawanishi H, Banshodani M, Moriishi M, Shintaku S. MP624THE RISK OF HOSPITALIZATION OF DAY-OF-WEEK IN HD AND PD PATIENTS IN 20 YEARS OBSERVATION. Nephrol Dial Transplant 2016. [DOI: 10.1093/ndt/gfw198.41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Kawanishi H, Moriishi M, Takahashi N, Tsuchiya S. The central dialysis fluid delivery system (CDDS): is it specialty in Japan? Ren Replace Ther 2016. [DOI: 10.1186/s41100-016-0016-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
37
|
Banshodani M, Kawanishi H, Moriishi M, Shintaku S, Ago R, Hashimoto S, Nishihara M, Tsuchiya S. Umbilical Hernia in Peritoneal Dialysis Patients: Surgical Treatment and Risk Factors. Ther Apher Dial 2015. [PMID: 26197840 DOI: 10.1111/1744-9987.12317] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
No previous reports have focused on surgical treatments and risk factors of umbilical hernia alone in peritoneal dialysis (PD) patients. Herein, we evaluated the treatments and risk factors. A total of 411 PD patients were enrolled. Of the 15 patients with umbilical hernia (3.6%), six underwent hernioplasty. There was no recurrence in five patients treated with tension-free hernioplasty. The mean PD vintage after onset of hernia in the hernioplasty group tended to be longer than that in the non-hernioplasty group. An incarcerated hernia occurred in one non-hernioplasty patient. Although the incidence was significantly higher among women (P = 0.02), female sex was not a risk factor for umbilical hernia (P = 0.08). Our findings suggest that umbilical hernias should be repaired for continuing PD. Furthermore, there were no significant risk factors for umbilical hernia in PD patients. Future studies with larger sample groups are required to elucidate these risk factors.
Collapse
Affiliation(s)
- Masataka Banshodani
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Hideki Kawanishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan.,Faculty of Medicine, Hiroshima University, Hiroshima, Japan
| | - Misaki Moriishi
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Sadanori Shintaku
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Rika Ago
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Shinji Hashimoto
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Masahiro Nishihara
- Department of Surgery, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | - Shinichiro Tsuchiya
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| |
Collapse
|
38
|
Kikuchi K, Akiba T, Nitta K, Masakane I, Ando R, Izumi N, Atsukawa M, Yamazaki C, Kato F, Hotta N, Tominaga Y, Orito E, Hora K, Nagasawa M, Kasahara H, Kawaguchi M, Kimura H, Ikebe N, Kawanishi H, Moriishi M, Shigemoto K, Harada T, Hirakata H, Watanabe H, Nosaki T, Tsubouchi H, Imawari M, Akizawa T. Multicenter Study of Pegylated Interferon α-2a Monotherapy for Hepatitis C Virus-Infected Patients on Hemodialysis: REACH Study. Ther Apher Dial 2014; 18:603-11. [DOI: 10.1111/1744-9987.12189] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Kan Kikuchi
- Department of Blood Purification; Kidney Center; Tokyo Women's Medical University; Tokyo Japan
- Shimoochiai Clinic; Tokyo Japan
| | - Takashi Akiba
- Department of Blood Purification; Kidney Center; Tokyo Women's Medical University; Tokyo Japan
| | - Kosaku Nitta
- Department of Medicine; Kidney Center; Tokyo Women's Medical University; Tokyo Japan
| | | | - Ryoichi Ando
- Department of Nephrology; Musashino Red Cross Hospital; Tokyo Japan
| | - Namiki Izumi
- Department of Gastroenterology and Hepatology; Musashino Red Cross Hospital; Tokyo Japan
| | - Masanori Atsukawa
- Division of Gastroenterology; Department of Internal Medicine; Nippon Medical School Chiba Hokusoh Hospital; Chiba Japan
| | | | - Fumi Kato
- Division of Nephrology; Department of Internal Medicine; Masuko Memorial Hospital; Aichi Japan
| | - Naoki Hotta
- Division of Hepatology; Department of Internal Medicine; Masuko Memorial Hospital; Aichi Japan
| | - Yoshihiro Tominaga
- Division of Endocrine Surgery; Department of Transplant and Endocrine Surgery; Nagoya Daini Cross Hospital; Aichi Japan
| | - Etsuro Orito
- Department of Gastroenterology; Nagoya Second Red Cross Hospital; Aichi Japan
| | - Kazuhiko Hora
- Department of Nephrology; Hokushin General Hospital; Nagano Japan
| | - Masaki Nagasawa
- Department of Nephrology; Shinonoi General Hospital; Nagano Japan
| | | | - Masanori Kawaguchi
- Department of Gastroenterology and Hepatology; Japanese Red Cross Kyoto Daiichi Hospital; Kyoto Japan
| | - Hiroyuki Kimura
- Department of Gastroenterology; Saiseikai Wakayama Hospital; Wakayama Japan
| | - Norisato Ikebe
- Division of Gastroenterology; Department of Surgery; Kochi Takasu Hospital; Kochi Japan
| | | | | | | | | | - Hideki Hirakata
- Division of Nephrology and Dialysis Center; Fukuoka Red Cross Hospital; Fukuoka Japan
| | - Hiroshi Watanabe
- Department of Gastroenterology and Hepatology; Fukuoka Red Cross Hospital; Fukuoka Japan
| | - Tsuyoshi Nosaki
- Digestive and Lifestyle Diseases; Kagoshima University Graduate School of Medicine and Dental Sciences; Kagoshima Japan
| | - Hirohito Tsubouchi
- Digestive and Lifestyle Diseases; Kagoshima University Graduate School of Medicine and Dental Sciences; Kagoshima Japan
| | - Michio Imawari
- Division of Gastroenterology; Department of Medicine; Showa University School of Medicine; Tokyo Japan
| | - Tadao Akizawa
- Division of Nephrology; Department of Medicine; Showa University School of Medicine; Tokyo Japan
| |
Collapse
|
39
|
Banshodani M, Kawanishi H, Moriishi M, Shintaku S, Sato T, Tsuchiya S. Intra-arterial treatment for massive subcutaneous hemorrhage in hemodialysis patients. Ther Apher Dial 2013; 18:284-90. [PMID: 24118763 DOI: 10.1111/1744-9987.12106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The incidence of acute massive hemorrhage in hemodialysis (HD) patients is thought to be higher than in healthy individuals, and a large, expanding subcutaneous hematoma can result in necrosis of the overlying skin. We evaluated the efficacy of intra-arterial treatment for acute massive subcutaneous hemorrhage in HD patients. Seven HD patients with subcutaneous hemorrhage following minor blunt trauma were treated using superselective transarterial embolization, between July 2005 and October 2012. After examining the site of the hemorrhage using contrast-enhanced computed tomography (CT), embolizations were performed using microcoils, gelatin sponges, or N-butyl cyanoacrylate. Hematoma evacuation or skin grafting was performed as needed. Four men and three women with a mean age of 70 years (range, 63-82 years) comprised the study population. Sites of bleeding were as follows: lower leg (N = 3), upper leg (N = 1), buttock (N = 1), precordia (N = 1), and forearm (N = 1). Blood transfusions were administered to five cases. All patients were successfully salvaged using transarterial embolization. Six patients underwent hematoma evacuation after transarterial embolization, and two patients underwent split-thickness skin grafting for skin necrosis. We established a treatment strategy for HD patients with acute subcutaneous hemorrhage. Immediate confirmation of the site and the degree of bleeding with contrast-enhanced CT and early treatment using the transarterial embolization and as needed, hematoma evacuation are effective for preventing skin necrosis in HD patients with acute subcutaneous hemorrhage.
Collapse
Affiliation(s)
- Masataka Banshodani
- Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
| | | | | | | | | | | |
Collapse
|
40
|
Banshodani M, Kawanishi H, Moriishi M, Shintaku S, Sato T, Tsuchiya S. Efficacy of Intra-Arterial Treatment for Massive Gastrointestinal Bleeding in Hemodialysis Patients. Ther Apher Dial 2013; 18:24-30. [DOI: 10.1111/1744-9987.12062] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- Masataka Banshodani
- Department of Artificial Organs; Akane-Foundation; Tsuchiya General Hospital; Hiroshima Japan
| | - Hideki Kawanishi
- Department of Artificial Organs; Akane-Foundation; Tsuchiya General Hospital; Hiroshima Japan
| | - Misaki Moriishi
- Department of Artificial Organs; Akane-Foundation; Tsuchiya General Hospital; Hiroshima Japan
| | - Sadanori Shintaku
- Department of Artificial Organs; Akane-Foundation; Tsuchiya General Hospital; Hiroshima Japan
| | - Tomoyasu Sato
- Department of Radiology; Akane-Foundation; Tsuchiya General Hospital; Hiroshima Japan
| | - Shinichiro Tsuchiya
- Department of Artificial Organs; Akane-Foundation; Tsuchiya General Hospital; Hiroshima Japan
| |
Collapse
|
41
|
Coentrao L, Ribeiro C, Santos-Araujo C, Neto R, Pestana M, Rahman E, Rahman H, Ahmed D, Mousa D, El Bishlawi M, Shibahara H, Shibahara N, Takahashi S, Dupuis E, Duval X, Dornic Q, Bonnal C, Lucet JC, Cerceau O, Randoux C, Balde C, Besson F, Mentre F, Vrtovsnik F, Koutroubas G, Malindretos P, Zagotsis G, Makri P, Syrganis C, Mambelli E, Mancini E, Elia C, Guadagno V, Facchini MG, Zucchelli A, Grazia M, Patregnani L, Santoro A, Stefan G, Stefan G, Stancu S, Capusa C, Ailioaiei OR, Mircescu G, Anwar S, Little C, Kingston R, Diwakar P, Kaikini R, Syrganis C, Koutroubas G, Zagotsis G, Malindretos P, Makri P, Nikolaou E, Loukas G, Sabry A, Alsaran K, Al Sherbeiny S, Abdulkader M, Kwak I, Song S, Seong E, Lee S, Lee D, Kim I, Rhee H, Silva F, Queiros J, Malheiro J, Cabrita A, Rocha A, Bamidis P, Bamidis P, Liaskos C, Chryssogonidis I, Frantzidis C, Papagiannis A, Vrochides D, Lasaridis A, Nikolaidis P, Malindretos P, Kotwal S, Muir C, Hawley C, Snelling P, Gallagher M, Jardine M, Shibata K, Shibata K, Toya Y, Umemura S, Iwamoto T, Ono S, Ikeda E, Kitazawa A, Kuji T, Koguchi N, Satta H, Nishihara M, Kawata S, Kaneda T, Yamada Y, Murakami T, Yanagi M, Yasuda G, Mathieu S, Yves D, Jean-Michel T, Nicolas Q, Jean-Francois C, Ibrahim M, Abdel Salam M, Awadalla A, Bichari W, Zaki S, Roca-Tey R, Samon R, Ibrik O, Roda A, Gonzalez-Oliva JC, Martinez-Cercos R, Viladoms J, Lin CC, Yang WC, Kim YO, Yoon SA, Yun YS, Song HC, Kim BS, Cheong MA, Ogawa T, Kiba T, Okazaki S, Hatano M, Iwanaga M, Noiri C, Matsuda A, Hasegawa H, Mitarai T, DI Napoli A, DI Lallo D, Tazza L, De Cicco C, Salvatori MF, Chicca S, Guasticchi G, Gelev S, Trajceska L, Srbinovska E, Pavleska S, Oncevski A, Dejanov P, Gerasomovska V, Selim G, Sikole A, Wilson S, Mayne T, Krishnan M, Holland J, Volz A, Good L, Nissenson A, Stavroulopoulos A, Aresti V, Maragkakis G, Kyriakides S, Rikker C, Rikker C, Juhasz E, Tornoci L, Tovarosi S, Greguschik J, Mag O, Rosivall L, Golebiowski T, Golebiowski T, Watorek E, Kusztal M, Letachowicz K, Letachowicz W, Madziarska K, Augustyniak Bartosik H, Krajewska M, Weyde W, Klinger M, Capitanini A, Lange S, Cupisti A, Schier T, Gobel G, Bosmuller C, Gruber I, Tiefenthaler M, Shipley T, Adam J, Sweeney D, Fenwick S, Mansy H, Ahmed S, Moore I, Iwamoto T, Shibata K, Yasuda G, Kaneda T, Murakami T, Kuji T, Koguchi N, Satta H, Nishihara M, Kawata S, Yanagi M, Yamada Y, Ono S, Ikeda E, Kitazawa A, Toya Y, Umemura S, Vigeral P, Saksi S, Flamant M, Boulanger H, Kim YO, Yoon SA, Yun YS, Song HC, Kim BS, Park WD, Cheong MA, Nikam M, Tavakoli A, Chemla E, Evans J, Malete H, Matyas L, Mogan I, Lazarides M, Ebner A, Shi Y, Shi Y, Zhang J, Cheng J, Frank LR, Melanie H, Dominique B, Michel G, Ikeda K, Yasuda T, Yotueda H, Nikam M, Ebah L, Jayanti A, Evans J, Kanigicherla D, Summers A, Manley G, Dutton G, Chalmers N, Mitra S, Checherita IA, Niculae A, Radulescu D, David C, Turcu FL, Ciocalteu A, Persic V, Persic V, Buturovic-Ponikvar J, Ponikvar R, Touam M, Touam M, Menoyo V, Drueke T, Rifaat M, Muresan C, Abtahi M, Koochakipour Z, Joly D, Baharani J, Rizvi S, Ng KP, Buzzi L, Sarcina C, Alberghini E, Ferrario F, Baragetti I, Santagostino G, Furiani S, Corghi E, Sarcina C, Terraneo V, Rastelli F, Bacchini G, Pozzi C, Adorati Menegato M, Mortellaro R, Locicero A, Romano A, Manzini PP, Steckiph D, Shintaku S, Kawanishi H, Moriishi M, Bansyodani M, Nakamura S, Saito M, Tsuchiya S, Barros F, Vaz R, Carvalho B, Neto R, Martins P, Pestana M, Likaj E, Likaj E, Seferi S, Rroji M, Idrizi A, Duraku A, Barbullushi M, Thereska N, Shintaku S, Kawanishi H, Moriishi M, Bansyodani M, Nakamura S, Saito M, Tsuchiya S. Vascular access. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Tanaka M, Itoh K, Matsushita K, Matsushita K, Moriishi M, Kawanishi H, Fukagawa M. Effects of Raloxifene on Bone Mineral Metabolism in Postmenopausal Japanese Women on Hemodialysis. Ther Apher Dial 2011; 15 Suppl 1:62-6. [DOI: 10.1111/j.1744-9987.2011.00929.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
43
|
Kawanishi H, Shintaku S, Moriishi M, Dohi K, Tsuchiya S. Seventeen years' experience of surgical options for encapsulating peritoneal sclerosis. Adv Perit Dial 2011; 27:53-58. [PMID: 22073830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Encapsulating peritoneal sclerosis (EPS) is a serious complication of long-term peritoneal dialysis (PD). The mortality rate for EPS has been high, primarily because of complications related to bowel obstruction. However recent advances in clinical research have established the pathogenesis and course of the condition and a treatment strategy. The final therapeutic option for EPS is surgical enterolysis, and we have performed 239 surgical procedures in 181 patients and observed favorable outcomes. Of 181 patients opting for surgery 64 (35.40%) died. Death was related to EPS in 33 patients (18.2%), including 14 who died postoperatively. The overall survival rate at 1, 2, 3, 5, and 8 years after diagnosis was 93%, 83%, 78%, 71%, and 60% respectively. The survival rate for EPS-related death at 1, 2, 3, 5, and 8 years after diagnosis was 95%, 90%, 87%, 81%, and 74% respectively. Median survival after diagnosis, considering death from any cause and death from EPS, was 43.9 months and 35.7 months respectively. In conclusion, we present favorable outcomes with EPS surgery in 181 patients encountered over a period of 17years. These data reconfirm that surgical treatment is essential for EPS patients. Encapsulating peritoneal sclerosis may no longer be a fatal complication and can be improved with accurate diagnosis and treatment.
Collapse
|
44
|
Moriishi M, Kawanishi H, Tsuchiya S. Impact of combination therapy with peritoneal dialysis and hemodialysis on peritoneal function. Adv Perit Dial 2010; 26:67-70. [PMID: 21348383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Peritoneal dialysis (PD) is a continuous, slow dialysis method advantageous for retaining residual renal function; however, after renal function is lost, increasing the PD dose is difficult, resulting in insufficient dialysis. The addition of hemodialysis (HD) to PD [combination therapy with PD and HD (PD+HD)] increases the ultrafiltration volume and optimizes the dialysis dose. Based on this situation, we have applied concomitant HD after loss of residual renal function in PD patients. In the present study, we investigated peritoneal function in patients who underwent PD+HD therapy. The subjects were 76 patients in whom PD+HD therapy continued for 6 months or longer. In PD+HD therapy, patients underwent PD 6 days each week and a 4-hour HD session once each week. The patients were divided into four groups based on their dialysate-to-plasma ratio of creatinine (D/P Cr) in a peritoneal equilibration test (PET) at the initiation of PD+HD therapy: high [H (n = 5)], high-average [HA (n = 29)], low-average [LA (n = 26)], and low [L (n = 16)]. Before and after initiation of PD+HD therapy, we measured PET D/P Cr values and effluent levels of fibrin degradation products (eFDPs) and cancer antigen 125 (eCA125) in the 4-hour PET effluent. In addition, we evaluated the ratio of overnight effluent to serum beta2-microglobulin (overnight D/P beta2MG) every year. In the H group, D/P Cr remained high after initiation of PD+HD therapy, but it declined significantly in the HA group and tended to decline in the LA and L groups. Overnight D/P beta2MG remained high in the H group after PD+HD therapy, but significantly declined in the HA group and remained unchanged in the LA and L groups. After PD+HD therapy initiation in the H group, eFDPs declined markedly, although that change was not significant. No decrease was noted in any other group. Peritoneal dialysis was discontinued in 33 of the 76 patients (43.4%) who underwent PD+HD therapy: in 5 of the 5 patients in the H group (100%), in 16 of 29 in the HA group (552%), in 7 of 26 in the LA group (26.9%), and in 5 of 16 in the L group (31.3%). On long-term follow-up, the PET D/P Cr tended to decrease in the H and LA groups; it did not change in the LA and L groups. No significant changes were noted in any group for overnight D/P beta2MG, eFDPs, or eCA125. We suggest that concomitant HD facilitates the continuation of PD treatment and the retention of peritoneal function in patients with uremic symptoms and excess body fluid associated with a loss of residual renal function. However, improvement in peritoneal function cannot be expected for patients in whom peritoneal function has already deteriorated. In those patients, a change of treatment method should be considered.
Collapse
|
45
|
Moriishi M, Kawanishi H, Tsuchiya S. Peritoneal dialysis patients with high effluent fibrin degradation products. Adv Perit Dial 2009; 25:41-44. [PMID: 19886315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Encapsulating peritoneal sclerosis (EPS) is a major and fatal complication of peritoneal dialysis (PD). For treatment, the efficacies of steroids, tamoxifen, immunosuppressants, and surgical total intestinal enterolysis have been reported, but the results have not been sufficient. Because treatment after the onset of EPS is limited, a prophylactic therapy is needed. We previously reported that the level of effluent fibrin degradation products (eFDPs) is predictive of EPS. In the present study, we investigated the clinical course of PD cases with high eFDP levels, and the effect of prophylactic steroid therapy against EPS. Between January 2002 and August 2008, we investigated 310 PD patients, of whom 22 had an eFDP level of 30 microg/mL or more in 4-hour effluent from a fast peritoneal equilibration test (PET). Mean patient age was 62.6 +/- 11.1 years, and mean duration of dialysis was 42.7 +/- 45.5 months (range: 1 - 202 months). During a fast PET performed every 6 months, we measured, in 4-hour effluent, eFDPs, cancer antigen 125 (eCA125), and dialysate-to-plasma creatinine (D/P Cr). In addition, we calculated D/P beta2-microglobulin (beta2MG) from levels in overnight dialysis effluent and blood. In the 22 cases, the mean eFDP level was 66.6 +/- 39.2 microg/mL; the D/P Cr 0.78 +/- 0.1; and the D/P beta2MG 0.45 +/- 0.2. Steroid (5 - 30 mg daily) was administered to 8 of the 22 patients. In the 8 treated cases, the eFDP level, the D/P Cr, and the D/P beta2MG declined, but did not return to normal, and EPS developed in 2 patients. The eFDP level was high when dialysis was introduced, but returned to normal in 2 of the remaining 14 patients. In 1 of the 14 cases, peritonitis developed 5 times, followed by rapid elevation in the eFDP level. The patient with this intractable peritonitis was switched to hemodialysis. The other 11 patients received no steroid therapy. In 1 of these 11 patients, the eFDP level declined, but not in the others. We suggest that active steroid therapy for patients with a high level of eFDPs may prevent EPS development.
Collapse
|
46
|
Eguchi K, Miyao M, Yamada Y, Konno Y, Kaneko I, Mineshima M, Taoka M, Sato T, Hagihara Y, Michiwaki H, Hanabusa R, Hosotani Y, Tao T, Tsuchida K, Minakuchi J, Tanigawa T, Miyamoto T, Moriishi M, Kawanishi H, Nakagawa A, Iwakuma K, Yoshida T, Imai Y, Obata H, Matsushima T. Clinical assessment of intermittent infusion hemodialysis (I-HD) using backfiltration of ultrapure dialysis fluid by an automated dialysis machine. ACTA ACUST UNITED AC 2009. [DOI: 10.4009/jsdt.42.695] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
47
|
Kawanishi H, Moriishi M, Sato T, Taoka M. Fully Automated Dialysis System Based on the Central Dialysis Fluid Delivery System. Blood Purif 2009; 27 Suppl 1:56-63. [DOI: 10.1159/000213499] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
48
|
Moriishi M, Kawanishi H. Icodextrin and intraperitoneal inflammation. Perit Dial Int 2008; 28 Suppl 3:S96-S100. [PMID: 18552274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
Abstract
BACKGROUND The peritoneum is impaired by exposure to biocompatible dialysis solutions. Because icodextrin peritoneal dialysis fluid (PDF) is made from cornstarch, a possibility that it induces intraperitoneal inflammation has been reported. In the present study, patients on glucose PDF were switched to icodextrin PDF and then switched back to glucose PDF. Icodextrin PDF-induced intraperitoneal inflammation was investigated based on changes in peritoneal permeability and inflammatory reactions. PATIENTS AND METHODS The subjects were 7 stable peritoneal dialysis patients (4 men, 3 women), with a mean age of 59.1 +/- 3.8 years (range: 55.2 - 64.6 years). The mean duration of peritoneal dialysis was 58.3 +/- 27.4 months (range: 34.3 - 97.7 months), and the cause of end-stage renal disease was chronic glomerulonephritis in all patients. For the overnight dwell, glucose PDF was changed to icodextrin PDF, and the patients returned to glucose PDF 30 months later. To evaluate peritoneal permeability, a peritoneal equilibrium test (PET) was performed, and dialysate-to-plasma (D/P) ratios of creatinine (Cr), beta(2)-microglobulin (beta2M), albumin, immunoglobulin G (IgG), and alpha(2)-macroglobulin (alpha2M) were measured in the overnight dialysate and serum. As markers of inflammation and fibrinolysis or coagulation, interleukin-6 (IL-6) and fibrinogen degradation products (FDPs) were measured in overnight effluent. The evaluations were made every 6 months for 36 months. RESULTS A significant elevation in FDP levels was detected in overnight effluent 6 months after the switch to icodextrin PDF, and IL-6 levels tended to increase. The D/P ratios of Cr, beta2M, and albumin were also significantly increased, and the D/P ratios of IgG and alpha2M tended to increase. The D/P ratio of Cr as measured by PET was slightly increased, but the elevation was not significant. In 5 patients, after icodextrin PDF was switched back to glucose PDF at 30 months, the D/P ratios of Cr, beta2M, albumin, IgG, and alpha2M in overnight effluent were significantly reduced. The FDP levels decreased slightly in those patients. In the remaining 2 patients, the D/P ratios of Cr on PET and of Cr, beta2M, albumin, IgG, and alpha2M in overnight effluent, and the FDP and IL-6 levels in overnight effluent were markedly elevated after the switching from glucose to icodextrin PDF, and they remained high after the switch back to glucose PDF. One of these 2 patients developed pre-EPS and was treated with prednisolone and concomitant hemodialysis. The other was switched from peritoneal dialysis to hemodialysis. CONCLUSIONS Icodextrin dialysis solution may induce an inflammatory reaction in the peritoneum. Further investigation is necessary for the long-term use of icodextrin PDF.
Collapse
|
49
|
Kawanishi H, Moriishi M, Ide K, Dohi K. Recommendation of the surgical option for treatment of encapsulating peritoneal sclerosis. Perit Dial Int 2008; 28 Suppl 3:S205-S210. [PMID: 18552257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
Abstract
Encapsulating peritoneal sclerosis (EPS) is an intestinal obstruction syndrome in which peritoneal deterioration and intraperitoneal inflammation result in intestinal adhesions, which are covered with a fibrin capsule and cause bowel obstruction. The widespread use of peritoneal dialysis (PD) has been associated with an increase in the number of patients with this life-threatening complication. For this reason, some negative comments have been made about PD therapy. However, recent clinical studies have elucidated the pathogenesis of EPS and proposed therapeutic strategies. Currently, these facts are known: EPS occurs in 2.5% of all patients (3.18/1000 patient-years). A longer duration of PD is associated with a higher incidence of EPS and a poorer prognosis, indicating the involvement of peritoneal deterioration in the development of EPS. Development of EPS involves some kind of infection. Development of EPS frequently occurs after PD withdrawal and catheter removal. Peritoneal lavage after PD withdrawal delays, but cannot prevent the development of EPS. Timely administration of steroids is effective. Surgical adhesiolysis is the optimal treatment to relieve bowel obstructions, but does not exclude the potential for re-adhesions, requiring various ingenious gastro-intestinal surgical techniques.
Collapse
|
50
|
Uchiyama-Tanaka Y, Mori Y, Kosaki A, Kimura T, Moriishi M, Kawanishi H, Matsubara H. Plasma S100A12 Concentrations in Peritoneal Dialysis Patients and Subclinical Chronic Inflammatory Disease. Ther Apher Dial 2008; 12:28-32. [DOI: 10.1111/j.1744-9987.2007.00537.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|